ClinicalTrials.gg
CompletedNCT06911866Updated Jan 30, 2026

A Phase Ib Study of RC1416 Injection

A Phase 1 interventional study of RC1416 and RC1416 Placebo in Moderate to Severe Asthma, sponsored by Nanjing RegeneCore Biotech Co., Ltd.. Completed at 16 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Nanjing RegeneCore Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.
  • Registered 5 months after the study started (first participant enrolled Oct 2024, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
154th of 182
40 · median 203
Started
2024
with 37 others
Phase 1
31 of 251
3 open now
Registered
202nd of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 154th largest by enrollment of the 182 interventional ones that give a count, is one of 38 that started in 2024, is one of 31 in phase 1, and was the 202nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RC1416 injection in patients with moderate to severe asthma.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled, ascending dose Phase Ib clinical study. RC1416 is a bispecific antibodies .It is being developed by Nanjing RegeneCore Biotech Co., Ltd. as a potential therapy for asthma. A total 40 patients with moderate to severe asthma will be enrolled in 4 groups to access the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of RC1416 injection.

03

Conditions studied

  • Moderate to Severe Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject fully understands the purpose, nature, methods and potential adverse events of the trial and voluntarily signs the form (ICF);
  2. Male or female patients aged ≥18 and ≤75 years at the time of ICF signing;
  3. The subject has been diagnosed with asthma for at least one year;
  4. The subject has been treated with medium to high-dose inhaled (ICS) (e.g.,fluticasone propionate ≥ 250 μg daily or equivalent ICS dose) in combination with at least one additional controller medication [such as long-acting β2 receptor agonists (LABA), long-acting anticholinergic drugs (LAMA), leukotriene receptor antagonists (LTRA), or sustained-release theophylline] for ≥ 3 months prior to ICF signing, with a stable dosing for ≥ 1 month before randomization;
  5. ACQ-6 score > 1.5 or ACT score \< 20 ;
  6. Pre-bronchodilator ≤ 80% of predicted value at screening;
  7. Positive objective tests for variable airflow obstruction within one year before randomization or during the screening period (including bronchodilation test, bronchial provocation test or peak expiratory flow variability, etc.).
  8. The subject agrees to take effective measures (as specified in the protocol) from the time of ICF signing until 6 months post-treatment.

Exclusion criteria

Exclusion Criteria:

  1. Based on the investigator's judgment,Clinically diagnosed with (COPD) or other lung diseases that may significantly impair lung function (such as atelectasis, pulmonary fibrosis, bronchopulmonary dysplasia, bronchiectasis, emphysema, etc.) ;
  2. Subjects who had required at least one systemic treatment due to asthma exacerbation or other reasons, or who had been hospitalized or treated emergency department due to asthma exacerbation within one month before administration;
  3. Subjects with a history of near-fatal asthma requiring endotracheal intubation and mechanical ventilation;
  4. Subjects who are Excessive dependence on short-acting β-agonists (SABA) (>10-12 puffs per day) , especially use more than one vial of salbutamol (or equivalent) per month;
  5. Subjects who used non-selective β-blockers within 1 month before screening until randomization;
  6. Subjects with pulmonary or other infection and oral or intravenous antibiotics or antifungal or antiviral drugs within one month before administration; Subjects have need local antibiotic or antiviral treatment within 7 days before screening;Subjects with a history of recurrent infections (≥3 times per year) and underlying diseases that predispose to infection; Subjects with a history of disseminated herpes simplex infection or recurrent (>1 time) or disseminated herpes zoster; Subjects with a history of opportunistic infections;
  7. Subjects who underwent major surgery within 6 months prior to screening or planned major surgery during the trial.
  8. Subjects who have suffered form within 5 years,except:

    • Subjects with cervical carcinoma in situ that has been completely resected and has no evidence of recurrence or for at least 3 years;
    • Subjects with basal cell or squamous cell carcinoma that have been completely resected and have no recurrence for at least 3 years;
    • Subjects with a history of cancer who have had complete remission of their malignant tumors for at least 5 years at the time of screening and have no anti-tumor treatment;
  9. Currently receiving or having received any of the prohibited drugs or treatments in this trial within the following time frames :

    1. , attenuated live vaccines, or adenovirus vector vaccines within 3 months prior to screening or plan to receive such vaccines during the trial;
    2. Any of the following drugs within 3 months or 5 half-lives (whichever is longer) prior to screening: IL-4Rα antagonists, IL-5/interleukin-5 receptor (IL-5R) antagonists, anti-IgE monoclonal antibodies, anti-TSLP antibodies, etc.;
    3. Bronchial thermoplasty within 3 years prior to screening;
    4. Allergen immunotherapy within 3 months prior to screening or plan to receive such treatments during the trial;
    5. Drugs that affect immunity within 3 months or 5 half-lives (whichever is longer) prior to screening, including but not limited to systemic /immunomodulatory drugs (including but not limited to methotrexate, cyclosporine, etc.);
    6. Montelukast within 2 weeks prior to screening;
    7. Immunoglobulin products within 3 months prior to screening;
    8. Traditional Chinese medicine or herbal products that affect bronchospasm and/or lung function within 1 month prior to screening.
  10. Subjects who have received any drug or participated in other clinical trials or medical research activities within 3 months or 5 half-lives (whichever is longer) before screening, or plan to participate in other drug or medical device clinical trials during the trial; except subjects who have only signed the ICF and participated in the screening of clinical trials but did not receive clinical trial treatment or enrollment within 3 months before the first dose.
  11. Subjects who have donated blood or lost blood ≥ 400 mL (excluding menstrual blood loss), or received blood transfusion or used blood products within 3 months before screening, or plan to donate blood during the study or within 1 month after the end of the trial.
  12. Current smokers or subjects who quit smoking within 6 months before screening, or previous smokers who quit smoking more than 6 months at screening with a smoking history > 10 pack-years (pack-years = number of packs smoked per day × number of years of smoking, 20 cigarettes per pack), or who cannot quit smoking during the trial.
  13. Subjects with known to be allergy to the or ingredients of this product, or have had severe drug or food allergic reactions in the past.
  14. With any psychological disorders or neurological/psychiatric disorders confirmed by the investigator.
  15. Subjects who have difficulty with venous blood collection,or are afraid of needles or blood, or those who have difficulty with subcutaneous injection administration.
  16. Any of the following abnormal in laboratory test results at screening or baseline:

    1. \< 90 g/L;
    2. count \< 100 × 109/L;
    3. (ANC) \< 1.2 × 109/L;
    4. (AST) or alanine aminotransferase (ALT) > 2.5 × (upper limit of normal);
    5. Serum creatinine > 1.5 × ULN;
    6. Total > 1.5 × ULN;
    7. Other laboratory test results abnormalities are , and the investigator judge that the subject are unsuitable for enrollment.
  17. Subject with clinically significant abnormalities in the 12-lead at screening or baseline as judged by the investigator , or prolonged ( QTcF interval >450 ms for males and >470 ms for females, Corrected by Fridericia,s formula), or a history of long QT syndrome.
  18. Any one of infectious disease screening indicators meets the following criteria at screening:

    1. According to the judgment of the investigator, there is vidence of active tuberculosis or a history of active tuberculosis without appropriate treatment, and screening results suggest the possibility of latent tuberculosis infection as judged by the investigator;
    2. Positive for surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and hepatitis B virus deoxyribonucleic acid (HBV DNA) exceeds the detection limit;
    3. antibody (HCVAb) positive and hepatitis C virus ribonucleic acid (HCV RNA) exceeds the detection limit;
    4. Positive for Treponema pallidum (Tp) antibody;
    5. Positive for antigen (HIVAg) or human immunodeficiency virus antibody (HIVAb).
  19. Subject with previous history of drug abuse/drug use;
  20. Subject with a history of alcoholism within 6 months prior to screening[(i.e., more than 14 standard units per week for women and more than 21 standard units per week for men (1 standard unit containing 14g of alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine) ]or those who cannot abstinence during the trial;
  21. Pregnant or lactating women, or those with a positive pregnancy test result;
  22. Other situations that the investigator judged are unsuitable for participating in this trial
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    RC1416

    Drug: RC1416

  • Placebo comparator
    Placebo

    Drug: RC1416 Placebo

Interventions

  • DrugRC1416

    there are four doses(200mg-400mg) in this part. Each subjects will receive the drug once by subcutaneous injection.

  • DrugRC1416 Placebo

    Each subjects will receive the placebo once by subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. AE

    incidence ,severity and relation to investigational drugs of Adverse Events according to CTCAE V5.0

    Time frame: up to 141 days

  2. SAE

    incidence ,severity and relation to investigational drugs of Adverse Events according to CTCAE V5.0

    Time frame: up to 141 days

  3. Vital Signs

    number of praticipants with clinically notable Vital Signs according to CTCAE V5.0

    Time frame: up to 141 days

  4. Laboratory Tests

    number of praticipants with clinically Laboratory Tests Values according to CTCAE V5.0

    Time frame: up to 141 days

  5. ECG

    number of praticipants with clinically notable Electrocardiogram(ECG) Values according to CTCAE V5.0

    Time frame: up to 141 days

  6. Injection Site Reaction

    number of praticipants with clinically notable Injection Site Reaction according to CTCAE V5.0

    Time frame: up to 85 days

Secondary outcomes

  1. Cmax

    maximum serum concentration

    Time frame: up to 141 days

  2. AUC0-t

    AUC extrapolated to infinitymeasurable concentration

    Time frame: up to 141 days

  3. AUC0-inf

    area under the concentration-time curve (AUC) from administration to the last measurable concentration

    Time frame: up to 141 days

  4. Anti-Drug antibody (ADA)

    number and percentage of subjects tested ADA positive

    Time frame: up to 141 days

  5. Tmax

    time to reach maximum concentration

    Time frame: up to 141 days

  6. t1/2

    the terminal elimination half-life

    Time frame: up to 141 days

  7. MRT

    mean residence time

    Time frame: up to 141 days

  8. λz

    elimination rate constant

    Time frame: up to 141 days

  9. CL/F

    apparent clearance

    Time frame: up to 141 days

  10. Vz/F

    apparent volume of distribution

    Time frame: up to 141 days

  11. Change from baseline in fractional exhaled nitric oxide (FeNO)

    Preliminary effectiveness indicators

    Time frame: up to 141 days

  12. Change from baseline in total IgE (immunoglobulin E), human thymus and activation-regulated chemokine (TARC)

    Preliminary effectiveness indicators

    Time frame: up to 141 days

  13. Change from baseline in blood eosinophil (EOS) count, free or bound IL-5 and total IL-5, and free IL-4 and IL-13 levels

    Preliminary effectiveness indicators

    Time frame: up to 141 days

07

Study locations

16 sites
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
  • Peking University Shougang Hospital
    Beijing, Beijing Municipality, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
  • The First Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
  • Hebei Petro China Centre Hospital
    Langfang, Hebei, China
  • Hebei Province Hospital of Chinese Medicine
    Shijiazhuang, Hebei, China
  • Nanyang Central Hospital
    Nanyang, Henan, China
  • Xinxiang First People's Hospital
    Xinxiang, Henan, China
  • The First Affiliated Hospital of Baotou Medical College
    Baotou, Inner Mongolia, China
  • Nanjing First Hospital
    Nanjing, Jiangsu, China
  • Jining NO.1 people's hospital
    Jining, Shandong, China
  • Liaocheng People's Hospital
    Liaocheng, Shandong, China
  • Zibo Municipal Hospital
    Zibo, Shandong, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
  • The Second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Sep 2025, 11 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 11 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 4, 2025
StartActual
Oct 25, 2024
Primary completionActual
Sep 25, 2025
CompletionActual
Sep 25, 2025
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06911866
Lead sponsor
Nanjing RegeneCore Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Oct 25, 2024
Primary completion
Sep 25, 2025
Completion
Sep 25, 2025
Last update
Jan 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RC1416

Start the discussion